UroGen Pharma
URGN
78 hedge funds and large institutions have $140M invested in UroGen Pharma in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 21 closing their positions.
25% more call options, than puts
Call options by funds: $5K | Put options by funds: $4K
2.69% more ownership
Funds ownership: 63% → 65.68% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 22
16% less funds holding
Funds holding: 93 → 78 (-15)
41% less capital invested
Capital invested by funds: $237M → $140M (-$96.5M)
67% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$14.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.74M |
| 3 |
Cerity Partners
New York
|
+$1.67M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$653K |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$522K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.5M |
| 2 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$1.83M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$1.26M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.12M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$964K |
URGN Hedge Fund Activity: Q4 2021 in Review
78 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2021, worth a combined $140M — down 41% from $237M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of URGN and 7 opened new positions — a net loss of 14 holders — while 22 trimmed existing stakes and 21 added.
The largest buyer was Harel Insurance Investments & Financial Services, opening a new position worth an estimated $14.5M. The largest seller was VOYA Investment Management, exiting entirely with an estimated $2.5M sold.
- 78 institutional investors held UroGen Pharma (URGN) as of Q4 2021, down from 93 in Q3 2021.
- Funds reported $140M of UroGen Pharma stock for Q4 2021, down 41% quarter-over-quarter.
- 7 funds opened new UroGen Pharma positions in Q4 2021 and 21 closed out, a net change of -14 holders.
- The largest UroGen Pharma buyer in Q4 2021 was Harel Insurance Investments & Financial Services, an estimated $14.5M added.
- The largest UroGen Pharma seller in Q4 2021 was VOYA Investment Management, an estimated $2.5M sold.
Based on aggregated 13F filings for Q4 2021.